{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:05:28Z","timestamp":1789239928206,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.amjcard.2023.07.141","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:12:28Z","timestamp":1694409148000},"page":"132-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-0781","authenticated-orcid":false,"given":"Mustafa","family":"Suppah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakan","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.A.","family":"Baradeiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishoy","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Alsidawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sorajja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. David","family":"Fortuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.07.141_bib0001","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","article-title":"Direct oral anticoagulants: a quick guide","volume":"12","author":"Julia","year":"2017","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002776","article-title":"Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions","volume":"5","author":"Di Biase","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0004","first-page":"524","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"75","author":"Vahanian","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0005","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0006","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0007","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0008","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study","volume":"16","author":"Dur\u00e3es","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0010","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0012","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0013","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0014","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: Findings from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) Trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ahj.2020.10.001","article-title":"A randomized clinical trial to evaluate the efficacy and safety of Rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: rationale and design of the RIVER trial","volume":"231","author":"Guimar\u00e3es","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.899906","article-title":"An updated meta-analysis of DOACs vs. VKAs in atrial fibrillation patients with bioprosthetic heart valve","volume":"9","author":"Cao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2020.104540","article-title":"The genus Daphne: a review of its traditional uses, phytochemistry and pharmacology","volume":"143","author":"Moshiashvili","year":"2020","journal-title":"Fitoterapia"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0018","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtcvs.2021.05.051","article-title":"Bioprosthetic valves and atrial fibrillation: direct anticoagulants or warfarin","volume":"165","author":"Kapadia","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0019","first-page":"e14651","article-title":"Systematic review and meta-analysis: can we compare direct oral anticoagulants to warfarin in patients with atrial fibrillation and bio-prosthetic valves?","volume":"13","author":"Adhikari","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0020","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Available at: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9781119536604. Accessed on May 1, 2023."},{"key":"10.1016\/j.amjcard.2023.07.141_bib0021","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0022","unstructured":"NIH. Study quality assessment tools. Available at: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed on May 1, 2023."},{"key":"10.1016\/j.amjcard.2023.07.141_bib0023","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0024","unstructured":"The Cochrane Collaboration; 2020. Review Manager (RevMan) [computer program]. version 5.4. Available at: RevMan | Cochrane Training. Accessed on May 1, 2023."},{"key":"10.1016\/j.amjcard.2023.07.141_bib0025","unstructured":"Butts CT. network: Classes for Relational Data [Internet]. The Statnet Project. Available at: https:\/\/cran.r-project.org\/web\/packages\/network\/index.html. Accessed on May 1, 2023."},{"key":"10.1016\/j.amjcard.2023.07.141_bib0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amjcard.2021.01.016","article-title":"Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves","volume":"146","author":"Duan","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0027","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1253\/circj.CJ-21-0564","article-title":"Antithrombotic therapy for patients with atrial fibrillation and bioprosthetic valves - real-world data from the multicenter, prospective, observational BPV-AF registry","volume":"86","author":"Izumi","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0028","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0029","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.jcin.2020.09.013","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR","volume":"13","author":"Kawashima","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0030","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.amjcard.2018.12.042","article-title":"Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation","volume":"123","author":"Mangner","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0031","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.athoracsur.2021.03.016","article-title":"New oral anticoagulants versus warfarin in atrial fibrillation after early postoperative period in patients with bioprosthetic aortic valve","volume":"113","author":"Mannacio","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0032","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026666","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair","volume":"11","author":"Mentias","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0033","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268113","article-title":"Effectiveness and safety of non-vitamin K direct oral anticoagulants in atrial fibrillation patients with bioprosthetic valve","volume":"17","author":"Moon","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0035","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.athoracsur.2020.12.031","article-title":"Non\u2013vitamin K antagonist oral anticoagulant vs warfarin for post cardiac surgery atrial fibrillation","volume":"112","author":"Nauffal","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0036","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijcard.2016.02.005","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease","volume":"209","author":"Noseworthy","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0037","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40261-020-00939-x","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements","volume":"40","author":"Pasciolla","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0038","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","article-title":"Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves","volume":"41","author":"Russo","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0039","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcin.2016.10.023","article-title":"Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement","volume":"10","author":"Seeger","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2021.01.127","article-title":"Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial","volume":"165","author":"Shim","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0041","doi-asserted-by":"crossref","first-page":"f93","DOI":"10.1093\/ehjcvp\/pvaa011","article-title":"All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease","volume":"7","author":"Strange","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0042","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023561","article-title":"Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS\/ACC TVT Registry","volume":"11","author":"Tanawuttiwat","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0043","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10840-020-00833-8","article-title":"Periprocedural and long-term safety and feasibility of direct oral anticoagulants in patients with biological valve undergoing radiofrequency catheter ablation for atrial fibrillation: a prospective multicenter study","volume":"61","author":"Di Biase","year":"2021","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0044","doi-asserted-by":"crossref","first-page":"355","DOI":"10.5603\/CJ.a2021.0158","article-title":"NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement","volume":"29","author":"Piepiorka-Broniecka","year":"2022","journal-title":"Cardiol J"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvz064","article-title":"Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation","volume":"7","author":"Butt","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262580","article-title":"Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-a SWEDEHEART study","volume":"17","author":"Christersson","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0047","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1253\/circj.CJ-22-0226","article-title":"Comparison of direct oral anticoagulants and warfarin in patients with atrial fibrillation and an aortic bioprosthetic valve","volume":"86","author":"Miyake","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0048","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1253\/circj.CJ-21-0716","article-title":"Additional effects of antiplatelet therapy on anticoagulant agents in patients with bioprosthetic valves and atrial fibrillation","volume":"86","author":"Amano","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0049","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10557-020-07038-1","article-title":"Rationale, design, and baseline characteristics of the bioprosthetic valves with atrial fibrillation (BPV-AF) study","volume":"34","author":"Furukawa","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jjcc.2020.02.006","article-title":"Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves: A retrospective observational study","volume":"76","author":"Izumi","year":"2020","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0051","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1160\/TH16-01-0007","article-title":"Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire valley atrial fibrillation project","volume":"115","author":"Philippart","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0054","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/STROKEAHA.116.014643","article-title":"Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation","volume":"48","author":"Pennlert","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0055","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1615261","article-title":"Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves\/prior surgical valve repair: a multicenter clinical practice experience","volume":"44","author":"Russo","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0056","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00392-015-0919-z","article-title":"Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves","volume":"105","author":"Yadlapati","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0057","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2015.07.006","volume":"170","author":"Bansilal","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0058","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.12.006","article-title":"Meta-analysis of direct oral anticoagulants in patients with atrial fibrillation and bioprosthetic valves","volume":"142","author":"Kheiri","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0059","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0735-1097(21)03049-7","article-title":"Non-vitamin K antagonists should be preferred over warfarin in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis","volume":"77","author":"Cardoso","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.141_bib0060","doi-asserted-by":"crossref","unstructured":"Guardia Mart\u00ednez P, Avil\u00e9s Toscano AL, Mart\u00ednez Mayoral MA, Molt\u00f3 Miralles J. DOAC versus VKA in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis [published online February 17, 2023]. Rev Esp Cardiol (Engl Ed) doi:10.1016\/j.rec.2023.02.002.","DOI":"10.1016\/j.rec.2023.02.002"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923007117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923007117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:48:42Z","timestamp":1757573322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923007117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":58,"alternative-id":["S0002914923007117"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.141","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}